Sanofi

Sanofi-aventis

Sanofi-synthelabo

Olivier Venier

Eric Nicolai

Claudie Namane

Christophe Philippo

Alain Jean Braun

Olivier Crespin

Cecile Pascal

Francois Pacquet

Roberto Cecchi

Patrick Mougenot

Tiziano Croci

Philippe Bovy

Eykmar Fett

Michel Aletru

Stefan Gussregen

Philippe R Bovy

Sandor Batori

Zoltan Kapui

Tibor Szabo

Peter Aranyi

Zoltán Szlávik

Katalin Urban-Szabo

Maria Balogh

Michel Finet

Judit Bence

Zsuzsanna Tomoskozi

Cécile Pascal

Alain Braun

François Pacquet

The invention relates to indane compounds of formula (I): to their preparation and to their therapeutic use.

Acrylamide-substituted indane compounds and therapeutic use thereof

The present invention relates to compounds corresponding to formula (I). Process for the preparation thereof and therapeutic use thereof. The compounds are modulators of the activity of AMP-activated protein kinase (AMPK) and are useful for treating e.g. diabetes and obesity. 

Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases

The invention relates to compounds of formula (I), where A, Ar, Ar, R, R, R, R, R, R, R, Rand Rare as described herein, and pharmaceutical compositions thereof, methods of preparation thereof, and methods of use thereof.

Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I

The present invention relates to tetrahydroquinoxaline urea derivatives of formula (I) as defined herein, and, to their preparation and to their therapeutic application.

Substituted adamantanes and their therapeutic application

The invention relates to a compound of the general formula (I), as defined herein which is useful in modulating the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and are useful for treating pathologies in which such modulation is beneficial, as in the case of metabolic syndrome or of noninsulin-dependent type 2 diabetes. The invention also relates to pharmaceutical preparations containing such a compound, processes for preparing and intermediates useful in the preparation of a such a compound.

Tetrahydroquinoxaline urea derivatives as modulators of 11&#x3b2;-hydroxysteroid dehydrogenase type 1

The invention relates to tropane urea derivatives of general formula (I) and to the application thereof as modulators of the activity of 11&#x3b2;-hydroxysteroid dehydrogenose type 1 (11&#x3b2;HSD1).

Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1

The present invention relates to tetrahydroquinoxaline urea derivatives of Formula (I): as disclosed herein, to their preparation and to their therapeutic application.

Tetrahydroquinoxaline urea derivatives

The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11&#x3b2;-HSD1 is involved.

Substituted quinoxalines, their preparation and their therapeutical use as 11&#x3b2;HSD1 modulators

The present invention is related to a compound of formula (I) wherein R, R, R, R, R, R, R, R, p, r andare as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1).

Urea derivatives of tropane, their preparation and their therapeutic application

The present invention relates to substituted pyrimidine compounds of formula I useful as orexin receptor antagonists. The invention also relates to pharmaceutical compositions containing said compounds. 

Pyrimidine derivatives as orexin receptor antagonists

The invention relates to the compounds of general formula (I) where Rrepresents H, a (C1-C4)alkyl, &#x2014;CO(C1-C4)alkyl, (C1-C4)alkylphenyl or &#x2014;CO-phenyl group, said phenyl being optionally substituted, Rrepresents H, a halogen atom, an &#x2014;S(O)R, &#x2014;NHSOR, &#x2014;NHSO-phenyl or &#x2014;NHSO&#x2014;(C1-C4)alkylphenyl group where z is equal to 0, 1 or 2 and where Rrepresents a (C1-C4)alkyl group, said phenyl being optionally substituted; where n is equal to 0, 1 or 2, Rand Rrepresent H, a (C1-C4)alkyl, hydroxyl, cyano, phenyl, benzyl, piperidyl, &#x2014;CONH, &#x2014;CO-phenyl, &#x2014;COOR, &#x2014;CH(phenyl) (OH) and &#x2014;C(phenyl)(OH) group, or Rand Rform together an optionally substituted 6-membered aromatic ring, Rrepresents H, a (C1-C4)alkyl, phenyl or benzyl group, and B represents a 5- or 6-membered nitrogen-containing heterocycle or homocycle optionally fused with a phenyl Group or optionally substituted; their addition salts; their method of preparation and their therapeutic application.

Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics

The invention relates to compounds of general formula (I): 

Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof

The invention concerns phenoxypropanolamines of formula (I)in which Rrepresents a hydrogen, a group &#x2014;S(O)&#x2014;(C-C)alk-R', (R&#x2032; being H, phenyl or (C-C)alkoxy), &#x2014;NHSO&#x2014;(C-C)alk or NHCO(C-C)alk; m and n are each independently 0, 1 or 2; Rand Rindependently represent a hydrogen, a (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkoxy, hydrogen(C-C)alkoxy-(C-C)alkyl, mono- or di(C-C)alkamino(C-C)alkyl, pyrrolidino(C-C)alkyl, phenylamino or (C-C)alkenyl group, an aromatic or heteroaromatic group optionally substituted with a group R, an aralkyl or heteroaralkyl group optionally substituted with a group R, Rand Rcan also together constitute a saturated or unsaturated ring of 3 to 8 atoms possibly bearing a (C-C)alkyl, amino (C-C)alkyl, carbamoyl or benzyl substituent; Rrepresents a hydrogen or a halogen, or a group &#x2014;CO(C-C)alk or a group &#x2014;NHSO&#x2014;(C-C)alk; a group (C-C)alk, a group (C-C)alkoxy, a halogen, &#x2014;COOH, &#x2014;COO(C-C)alk, &#x2014;CN, &#x2014;CONRR, &#x2014;NO, &#x2014;SONHor &#x2014;NHSO(C-C)alk; z is 1 or 2; and the salts or solvates thereof. The compounds have agonist activity toward &#x3b2;-3 adrenergic receptors.

Growing community of inventors

Paris, France

Olivier Venier